Inhibition of inducible Nitric Oxide Synthase expression by an acetonic extract from Feijoa sellowiana Berg. fruits.

Feijoa sellowiana Berg. fruits and especially the acetonic extract have been shown to possess biological activities, although the responsible compounds have never been identified. The present study was designed to evaluate the anti-inflammatory activity of an acetonic extract from F. sellowiana Berg. fruits on the nitric oxide (NO) pathway, which plays an important role in inflammation. To this aim the J774 cell line, which expresses inducible nitric oxide synthase (iNOS) following stimulation with lipopolysaccharide (LPS), has been utilized, and the effects of this extract and its fractions on NO production, iNOS protein expression, and signal pathways involved in its regulation have been evaluated. This study demonstrates that at least some part of the anti-inflammatory activity of the acetonic extract is due to the suppression of NO production by flavone and stearic acid. The mechanism of this inhibition seems to be related to an action on the expression of the enzyme iNOS through the attenuation of nuclear factor κB (NF-κB) and/or mitogen-activated protein kinase (MAPK) activation

Volatile components from aerial parts of Centaurea spinosociliata Seenus ssp. cristata (Bartl.) Dostál and Centaurea spinosociliata Seenus ssp. spinosociliata growing wild in Croatia

The paper reports on the volatile components oil from aerial parts of two Asteraceae growing wild in Croatia: Centaurea spinosociliata ssp. cristata (syn. Centaurea cristata Bartl. subsp. rabenhorstiana (Sch.Bip.) Nyman) (CSC) and C. spinosociliata ssp. spinosociliata (CSS). The volatile components were obtained by hydrodistillation from selected plants and were determined by the GC-MS system on two fused-silica capillary columns of different polarity. The oil content was 0.08 % (CSC) and 0.07 % (CSS) on a dry weight basis. Altogether 73 compounds were identified accounting for 90.8 % (CSC) and 92.8 % (CSS) of the total oil, that were characterized mainly by hydrocarbons (37.9 %; 30.4 %), sesquiterpene hydrocarbons (14.1 %; 29.1 %), oxygenated sesquiterpenes (22.2 %; 13.1 %). The major components of the samples were heptacosane (11.2 %; 12.6 %), cyclosativene (2.1 %; 6.4 %), caryophyllene oxide (10.2 %; 4.7 %). Monoterpenes, fatty acids and phenolic compounds were absent or present in low amount in both oils. The chemotaxonomy of the subgenus Acrolophus is briefly discussed

Analysis of essential oils from Scutellaria orientalis ssp. alpina and S. utriculata by GC and GC-MS.

The chemical composition of the essential oils obtained from aerial parts of Scutellaria orientalis L. ssp. alpina (Boiss.) O. Schwarz and S. utriculata Labill. growing wild in Lebanon, were analyzed by GC and GC-MS. In S. orientalis ssp. alpina, strongly characterized by sesquiterpenes (41.2%) and particularly sesquiterpene hydrocarbons (31.7%), hexahydrofarnesylacetone (11.7%) was recognized as the main constituent, together with hexadecanoic acid (7.6%), caryophyllene (7.4%), caryophyllene oxide (6.8%), 4-vinylguaiacol (5.4%) and germacrene D (5.4%). S. utriculata oil was instead constituted above all by monoterpenes (42.2%), particularly oxygen containing monoterpenes (39.9%), and in this oil the main compounds were linalool (20.1%), 4-vinyl guaiacol (15.5%), α-terpineol (8.9%), ( E)-nerolidol (8.9%) and geraniol (8.2%)

Cytotoxic properties of Marrubium globosum ssp. libanoticum and its bioactive components

Marrubium globosum Montbr. et Auch. ex Benth. ssp. libanoticum Boiss. (Lamiaceae) is a medicinal plant used in Lebanon for the treatment of inflammatory diseases, asthma, coughs and other pulmonary and urinary problems. The goal of our study was to assess the biological activity of M. globosum by testing different extracts of the aerial parts for their antiproliferative activity against human melanoma cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The chloroform fraction showed the greatest activity. The compounds isolated from the extracts were also tested: the mixture of (13 S)-9α,13α-epoxylabda-6β(19),16(15)-diol dilactone and (13 R)-9α,13α-epoxylabda-6β(19),16(15)-diol dilactone was the most active fraction, with an IC50 value of 29.2 ± 0.06 μg/mL

Volatile components from aerial parts of Centaurea spinosociliata Seenus ssp. cristata (Bartl.) Dostál and Centaurea spinosociliata Seenus ssp. spinosociliata growing wild in Croatia

The paper reports on the volatile components oil from aerial parts of two Asteraceae growing wild in Croatia: Centaurea spinosociliata ssp. cristata (syn. Centaurea cristata Bartl. subsp. rabenhorstiana (Sch.Bip.) Nyman) (CSC) and C. spinosociliata ssp. spinosociliata (CSS). The volatile components were obtained by hydrodistillation from selected plants and were determined by the GC-MS system on two fused-silica capillary columns of different polarity. The oil content was 0.08 % (CSC) and 0.07 % (CSS) on a dry weight basis. Altogether 73 compounds were identified accounting for 90.8 % (CSC) and 92.8 % (CSS) of the total oil, that were characterized mainly by hydrocarbons (37.9 %; 30.4 %), sesquiterpene hydrocarbons (14.1 %; 29.1 %), oxygenated sesquiterpenes (22.2 %; 13.1 %). The major components of the samples were heptacosane (11.2 %; 12.6 %), cyclosativene (2.1 %; 6.4 %), caryophyllene oxide (10.2 %; 4.7 %). Monoterpenes, fatty acids and phenolic compounds were absent or present in low amount in both oils. The chemotaxonomy of the subgenus Acrolophus is briefly discussed

Chemical Composition of the Essential Oil from Aerial Parts of Stachys palustris L. (Lamiaceae) Growing Wild in Southern Italy

The paper reports the composition of the essential oil from aerial parts of Stachys palustris L. (Lamiaceae) from Southern Italy. The essential oil was extracted by hydrodistillation from selected plants and its chemical composition was determined by the GC-MS system on two fused- silica capillary columns of different polarity. The mass fraction of oil was 0.21 % on a dry weight basis. Altogether, 92 compounds were identified accounting for 93.6 % of the total oil, which was characterized mainly by carbonylic compounds (25.4 %), fatty acids and their esters (24.2 %), along with sesquiterpenoidic compounds (16.0 %) and phenols (11.2 %). The major components of the sample were caryophyllene oxide (7.8 %), hexahydrofarnesyl acetone (7.4 %), hexadecanoic acid (6.8 %), (Z,Z,Z)-9,12,15-octadecatrienoic acid (6.7 %), (Z)-phytol (6.4 %), thymol (5.8 %), p-methoxyacetophenone (5.1 %), 4-vinylguiacole (3. %), tetradecanoic acid (3.8 %), (E)-caryophyllene (3.6 %), b-ionone (3.3 %) and b-damascenone (3.0 %)

Primordial fluctuations and non-Gaussianities from multifield DBI Galileon inflation

We study a cosmological scenario in which the DBI action governing the motion of a D3-brane in a higher-dimensional spacetime is supplemented with an induced gravity term. The latter reduces to the quartic Galileon Lagrangian when the motion of the brane is non-relativistic and we show that it tends to violate the null energy condition and to render cosmological fluctuations ghosts. There nonetheless exists an interesting parameter space in which a stable phase of quasi-exponential expansion can be achieved while the induced gravity leaves non trivial imprints. We derive the exact second-order action governing the dynamics of linear perturbations and we show that it can be simply understood through a bimetric perspective. In the relativistic regime, we also calculate the dominant contribution to the primordial bispectrum and demonstrate that large non-Gaussianities of orthogonal shape can be generated, for the first time in a concrete model. More generally, we find that the sign and the shape of the bispectrum offer powerful diagnostics of the precise strength of the induced gravity.Comment: 34 pages including 9 figures, plus appendices and bibliography. Wordings changed and references added; matches version published in JCA

Accelerating Universe and Cosmological Perturbation in the Ghost Condensate

In the simplest Higgs phase of gravity called ghost condensation, an accelerating universe with a phantom era (w<-1) can be realized without ghost or any other instabilities. In this paper we show how to reconstruct the potential in the Higgs sector Lagrangian from a given cosmological history (H(t), \rho(t)). This in principle allows us to constrain the potential by geometrical information of the universe such as supernova distance-redshift relation. We also derive the evolution equation for cosmological perturbations in the Higgs phase of gravity by employing a systematic low energy expansion. This formalism is expected to be useful to test the theory by dynamical information of large scale structure in the universe such as cosmic microwave background anisotropy, weak gravitational lensing and galaxy clustering.Comment: 30 pages; typos corrected; version accepted for publication in JCA

ITALIAN CANCER FIGURES - REPORT 2015: The burden of rare cancers in Italy = I TUMORI IN ITALIA - RAPPORTO 2015: I tumori rari in Italia

OBJECTIVES: This collaborative study, based on data collected by the network of Italian Cancer Registries (AIRTUM), describes the burden of rare cancers in Italy. Estimated number of new rare cancer cases yearly diagnosed (incidence), proportion of patients alive after diagnosis (survival), and estimated number of people still alive after a new cancer diagnosis (prevalence) are provided for about 200 different cancer entities. MATERIALS AND METHODS: Data herein presented were provided by AIRTUM population- based cancer registries (CRs), covering nowadays 52% of the Italian population. This monograph uses the AIRTUM database (January 2015), which includes all malignant cancer cases diagnosed between 1976 and 2010. All cases are coded according to the International Classification of Diseases for Oncology (ICD-O-3). Data underwent standard quality checks (described in the AIRTUM data management protocol) and were checked against rare-cancer specific quality indicators proposed and published by RARECARE and HAEMACARE (www.rarecarenet.eu; www.haemacare.eu). The definition and list of rare cancers proposed by the RARECAREnet "Information Network on Rare Cancers" project were adopted: rare cancers are entities (defined as a combination of topographical and morphological codes of the ICD-O-3) having an incidence rate of less than 6 per 100,000 per year in the European population. This monograph presents 198 rare cancers grouped in 14 major groups. Crude incidence rates were estimated as the number of all new cancers occurring in 2000-2010 divided by the overall population at risk, for males and females (also for gender-specific tumours).The proportion of rare cancers out of the total cancers (rare and common) by site was also calculated. Incidence rates by sex and age are reported. The expected number of new cases in 2015 in Italy was estimated assuming the incidence in Italy to be the same as in the AIRTUM area. One- and 5-year relative survival estimates of cases aged 0-99 years diagnosed between 2000 and 2008 in the AIRTUM database, and followed up to 31 December 2009, were calculated using complete cohort survival analysis. To estimate the observed prevalence in Italy, incidence and follow-up data from 11 CRs for the period 1992-2006 were used, with a prevalence index date of 1 January 2007. Observed prevalence in the general population was disentangled by time prior to the reference date (≤2 years, 2-5 years, ≤15 years). To calculate the complete prevalence proportion at 1 January 2007 in Italy, the 15-year observed prevalence was corrected by the completeness index, in order to account for those cancer survivors diagnosed before the cancer registry activity started. The completeness index by cancer and age was obtained by means of statistical regression models, using incidence and survival data available in the European RARECAREnet data. RESULTS: In total, 339,403 tumours were included in the incidence analysis. The annual incidence rate (IR) of all 198 rare cancers in the period 2000-2010 was 147 per 100,000 per year, corresponding to about 89,000 new diagnoses in Italy each year, accounting for 25% of all cancer. Five cancers, rare at European level, were not rare in Italy because their IR was higher than 6 per 100,000; these tumours were: diffuse large B-cell lymphoma and squamous cell carcinoma of larynx (whose IRs in Italy were 7 per 100,000), multiple myeloma (IR: 8 per 100,000), hepatocellular carcinoma (IR: 9 per 100,000) and carcinoma of thyroid gland (IR: 14 per 100,000). Among the remaining 193 rare cancers, more than two thirds (No. 139) had an annual IR &lt;0.5 per 100,000, accounting for about 7,100 new cancers cases; for 25 cancer types, the IR ranged between 0.5 and 1 per 100,000, accounting for about 10,000 new diagnoses; while for 29 cancer types the IR was between 1 and 6 per 100,000, accounting for about 41,000 new cancer cases. Among all rare cancers diagnosed in Italy, 7% were rare haematological diseases (IR: 41 per 100,000), 18% were solid rare cancers. Among the latter, the rare epithelial tumours of the digestive system were the most common (23%, IR: 26 per 100,000), followed by epithelial tumours of head and neck (17%, IR: 19) and rare cancers of the female genital system (17%, IR: 17), endocrine tumours (13% including thyroid carcinomas and less than 1% with an IR of 0.4 excluding thyroid carcinomas), sarcomas (8%, IR: 9 per 100,000), central nervous system tumours and rare epithelial tumours of the thoracic cavity (5%with an IR equal to 6 and 5 per 100,000, respectively). The remaining (rare male genital tumours, IR: 4 per 100,000; tumours of eye, IR: 0.7 per 100,000; neuroendocrine tumours, IR: 4 per 100,000; embryonal tumours, IR: 0.4 per 100,000; rare skin tumours and malignant melanoma of mucosae, IR: 0.8 per 100,000) each constituted &lt;4% of all solid rare cancers. Patients with rare cancers were on average younger than those with common cancers. Essentially, all childhood cancers were rare, while after age 40 years, the common cancers (breast, prostate, colon, rectum, and lung) became increasingly more frequent. For 254,821 rare cancers diagnosed in 2000-2008, 5-year RS was on average 55%, lower than the corresponding figures for patients with common cancers (68%). RS was lower for rare cancers than for common cancers at 1 year and continued to diverge up to 3 years, while the gap remained constant from 3 to 5 years after diagnosis. For rare and common cancers, survival decreased with increasing age. Five-year RS was similar and high for both rare and common cancers up to 54 years; it decreased with age, especially after 54 years, with the elderly (75+ years) having a 37% and 20% lower survival than those aged 55-64 years for rare and common cancers, respectively. We estimated that about 900,000 people were alive in Italy with a previous diagnosis of a rare cancer in 2010 (prevalence). The highest prevalence was observed for rare haematological diseases (278 per 100,000) and rare tumours of the female genital system (265 per 100,000). Very low prevalence (&lt;10 prt 100,000) was observed for rare epithelial skin cancers, for rare epithelial tumours of the digestive system and rare epithelial tumours of the thoracic cavity. COMMENTS: One in four cancers cases diagnosed in Italy is a rare cancer, in agreement with estimates of 24% calculated in Europe overall. In Italy, the group of all rare cancers combined, include 5 cancer types with an IR&gt;6 per 100,000 in Italy, in particular thyroid cancer (IR: 14 per 100,000).The exclusion of thyroid carcinoma from rare cancers reduces the proportion of them in Italy in 2010 to 22%. Differences in incidence across population can be due to the different distribution of risk factors (whether environmental, lifestyle, occupational, or genetic), heterogeneous diagnostic intensity activity, as well as different diagnostic capacity; moreover heterogeneity in accuracy of registration may determine some minor differences in the account of rare cancers. Rare cancers had worse prognosis than common cancers at 1, 3, and 5 years from diagnosis. Differences between rare and common cancers were small 1 year after diagnosis, but survival for rare cancers declined more markedly thereafter, consistent with the idea that treatments for rare cancers are less effective than those for common cancers. However, differences in stage at diagnosis could not be excluded, as 1- and 3-year RS for rare cancers was lower than the corresponding figures for common cancers. Moreover, rare cancers include many cancer entities with a bad prognosis (5-year RS &lt;50%): cancer of head and neck, oesophagus, small intestine, ovary, brain, biliary tract, liver, pleura, multiple myeloma, acute myeloid and lymphatic leukaemia; in contrast, most common cancer cases are breast, prostate, and colorectal cancers, which have a good prognosis. The high prevalence observed for rare haematological diseases and rare tumours of the female genital system is due to their high incidence (the majority of haematological diseases are rare and gynaecological cancers added up to fairly high incidence rates) and relatively good prognosis. The low prevalence of rare epithelial tumours of the digestive system was due to the low survival rates of the majority of tumours included in this group (oesophagus, stomach, small intestine, pancreas, and liver), regardless of the high incidence rate of rare epithelial cancers of these sites. This AIRTUM study confirms that rare cancers are a major public health problem in Italy and provides quantitative estimations, for the first time in Italy, to a problem long known to exist. This monograph provides detailed epidemiologic indicators for almost 200 rare cancers, the majority of which (72%) are very rare (IR&lt;0.5 per 100,000). These data are of major interest for different stakeholders. Health care planners can find useful information herein to properly plan and think of how to reorganise health care services. Researchers now have numbers to design clinical trials considering alternative study designs and statistical approaches. Population-based cancer registries with good quality data are the best source of information to describe the rare cancer burden in a population